CABALETTA BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
CABALETTA BIO, INC. (CABA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $2.83 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-13
- CABALETTA BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $2.83, a 95.17% increase year-over-year.
- CABALETTA BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $1.45, a 92.65% decline year-over-year.
- CABALETTA BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $19.72, a 116.23% increase year-over-year.
- CABALETTA BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $9.12, a 314.55% increase year-over-year.
- CABALETTA BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $1.52, a 88.69% decline from fiscal 2024.
- CABALETTA BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $13.44, a 41.32% increase from fiscal 2023.
- CABALETTA BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $9.51, a 342.33% increase from fiscal 2022.
- CABALETTA BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $2.15.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.83 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | $2.83 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | $1.52 10-K · filed 2026-03-23 | |||
| 2025-09-30 | $1.46 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $1.46 10-Q · filed 2026-08-13 | |||
| 2025-03-31 | $1.45 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | $13.44 10-K · filed 2026-03-23 | |||
| 2024-09-30 | $15.61 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | $17.41 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | $19.72 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $9.51 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $9.27 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $9.13 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $9.12 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | $2.15 10-K · filed 2024-03-21 | |||
| 2022-09-30 | $2.10 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | $2.11 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | $2.20 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |